Syndax Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the quarter ended March 31, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities as set forth in the table below.
| Type of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position · Action · Adoption/Termination Date · Rule 10b5-1* · Non- Rule 10b5-1** · Total Shares of Common Stock to be Sold · Total Shares of Common Stock to be Purchased · Expiration Date | ||||||
| Michael A. MetzgerChief Executive Officer, Director | Amendment*** | 3/11/2025 | X | 157,307 | - | 9/9/2025 |
| Dennis PodlesakDirector | Adoption**** | 3/5/2025 | X | 65,600 | - | 3/31/2026 |
- Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
*** Mr. Metzger’s plan solely includes equity grants with expiration dates prior to September 10, 2025.
**** Mr. Podlesak’s plan solely includes equity grants with expiration dates prior to March 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.